TinniMizer : A Patient-specific Novel Approach for Tinnitus Treatment

Projektbeschreibung

Musiktherapie bei Tinnitus

Tinnitus ist das Phänomen, bei dem Geräusche vernommen werden, obwohl es keine äußere Geräuschquelle gibt. Der Schweregrad des Tinnitus ist nur schwer feststellbar und je nach Ursache gibt es unterschiedliche Behandlungsoptionen. Eine dauerhafte Heilung gibt es jedoch noch nicht und die Betroffenen sind oft nicht mehr in der Lage, zu arbeiten oder soziale Kontakte zu pflegen. Die sozioökonomischen Folgen liegen dabei auf der Hand. Das EU-finanzierte Projekt TinniMizer hat eine musiktherapeutische Behandlung erarbeitet, die kostengünstig und einfach anwendbar ist. Das System soll die negativen Auswirkungen des Tinnitus nach nur drei Behandlungsmonaten statt in eineinhalb Jahren lindern, wie es bei anderen klangtherapeutischen Systemen üblich ist.

Ziel

Tinnitus can be a debilitating condition, which negatively affects a patient’s overall health and social well-being. Even moderate cases can interfere with the ability to work and socialise. The financial consequences of tinnitus are significant. Personal economic loss to an individual with tinnitus--including lost earnings, productivity, and health expenses--can be up to €30,000 annually. The cost to society as a whole has been estimated at upwards of €26 billion annually. Despite these effects there is currently no scientifically proven cure for most cases of chronic tinnitus. The medical doctors (ENT specialists), audiologists, and electronics-biomedical engineers in Genmel Technology have developed a new, patient-specific, state-of-the-art, and patented musical therapy system called TinniMizer as a new treatment for Tinnitus due to a substantial need to cure the tinnitus with an easy-to-use and cost-effective therapeutic system. Preliminary results obtained from about 20 patients at three clinics (Tinnitus Treatment Centers) indicate that after using TinniMizer system for about 3 months, there is approximately 70% reduction in the complaints of tinnitus patients. Through this project, Genmel will further develop this therapy to result in over 95% reduction in tinnitus. In other sound therapy systems, the duration of therapy is 1.5 years. Our goal is to reduce this period to a much shorter period (up to 3 months). Genmel offers R&D solutions, productions, and consulting services especially in the field of Biomedical, Electronics, Medicine and Energy. Academicians, engineers and technicians are working in GENMEL. The main goal of GENMEL is to develop and bring to market new products, services and business models that could drive economic growth. Through this project, Genmel aims to achieve a total turnover of >€14.5 million by the 5th year of TinniMizer commercialization.

Wissenschaftliches Gebiet

medical and health sciencesclinical medicineotorhinolaryngology

Programm/Programme

Thema/Themen

EIC-SMEInst-2018-2020 - SME instrument

Aufforderung zur Vorschlagseinreichung

H2020-EIC-SMEInst-2018-2020

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEInst-2018-2020-1

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

GENMEL BIYOMEDIKAL TEKNOLOJI ARGE SANAYI VE TICARET LIMITED SIRKETI

Netto-EU-Beitrag

€ 50 000,00

Adresse

CIFTEHAVUZLAR MAH. ESKI LONDRA ASFALTI CAD. KULUCK ERC1 BLOK 151/1E/105
34220 ISTANBUL
Türkei

KMU

Ja

Region

İstanbul İstanbul İstanbul

Aktivitätstyp

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Die Organisation kontaktieren

Teilnahme an EU-FuI-Programmen

HORIZON-Kooperationsnetzwerk

Gesamtkosten

€ 71 429,00